Jr. Mark L. Lupher, Net Worth

The estimated Net Worth of Jr. Mark L. Lupher, is at least $914 millier dollars as of 7 February 2024. Jr Lupher owns over 130,000 units of Adverum Biotechnologies Inc stock worth over $913,900 and over the last 6 years Jr sold ADVM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jr Lupher ADVM stock SEC Form 4 insiders trading

Jr has made over 1 trades of the Adverum Biotechnologies Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Jr bought 130,000 units of ADVM stock worth $175,500 on 7 February 2024.

The largest trade Jr's ever made was buying 130,000 units of Adverum Biotechnologies Inc stock on 7 February 2024 worth over $175,500. On average, Jr trades about 14,444 units every 0 days since 2019. As of 7 February 2024 Jr still owns at least 130,000 units of Adverum Biotechnologies Inc stock.

You can see the complete history of Jr Lupher stock trades at the bottom of the page.

What's Jr Lupher's mailing address?

Jr's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.

Insiders trading at Adverum Biotechnologies Inc

Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard et Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.

What does Adverum Biotechnologies Inc do?

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Complete history of Jr Lupher stock trades at Adverum Biotechnologies Inc

Adverum Biotechnologies Inc executives and stock owners

Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:

• Leone Patterson,
  President
• Thomas Leung,
  Chief Financial Officer
• Aaron Osborne,
  Chief Medical Officer
• Dr. Laurent Fischer,
  Pres, CEO, Interim CMO & Director
• Dr. Brigit Riley Ph.D.,
  Chief Scientific Officer
• Rekha Hemrajani,
  Independent Director
• James Scopa,
  Independent Director
• Mark Lupher,
  Independent Director
• Patrick Machado,
  Independent Chairman of the Board
• Richard Spivey,
  Independent Director
• Eric Carter,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Mehdi Gasmi,
  Director
• Myesha Lacy,
  Vice President, Investor Relations and Corporate Communications
• Scott Whitcup,
  Independent Director
• Peter Soparkar,
  Chief legal officer
• Christopher Morrison,
  Vice President - Process Development
• Thomas Kochy,
  Vice President - Commercial and Program Strategy
• Heikki Jouttijarvi,
  Vice President - Manufacturing
• Angela Thedinga,
  Chief Technology Officer
• Laurent Fischer,
  Chief Executive Officer, Director
• Carla Fiankan,
  Sr. VP of Regulatory Affairs
• Nancy E. Pecota,
  Principal Accounting Officer
• John W. Rakow J.D.,
  Sr. VP, Gen. Counsel & Acting CFO
• Anand Reddi,
  VP, Head of Corp. Strategy & External Affairs and Engagement
• Michael Steel,
  Sr. VP of Quality
• Dr. Jim Wang Ph.D.,
  Sr. VP & Head of Regulatory Affairs
• Dena House,
  Sr. VP of HR, Organizational Devel. & Learning
• Kishor Peter Soparkar J.D.,
  Chief Operating Officer
• Dr. Rupert D'Souza M.B.A., Ph.D.,
  Chief Financial Officer
• Steven Daniel Schwartz,
  Director
• Samuel B. Barone,
  SVP, Clinical Development
• Athena Countouriotis,
  SVP, Chief Medical Officer
• Mitchell H. Finer,
  Director
• Carlo Russo,
  EVP and Chief Medical Officer
• Jennifer C. Cheng,
  General Counsel
• Amber Salzman,
  President and CEO
• Paul B Cleveland,
  Chief Executive Officer
• Richard Beckman,
  Chief Medical Officer
• Szilard Kiss,
  
• Soo Hong,
  
• Rabia Gurses Ozden,
  Chief Medical Officer
• Linda M Rubinstein,
  CHIEF FINANCIAL OFFICER
• Dawn Svoronos,
  
• Reed Vaughn Tuckson,
  
• Rupert D'souza,
  Chief Financial Officer
• Julie Clark,
  Chief Medical Officer
• Setareh Seyedkazemi,
  CHIEF DEVELOPMENT OFFICER
• Braden Michael Leonard,
  
• Brigit Riley,
  Chief Scientific Officer
• John Rakow,
  SVP, Genl Counsel, Acting CFO
• C. David Nicholson,,